morning, Good the and some by joining performance had on results, providing Building on today. Mark, then us first a I'll of the quarter. Steve XXXX, followed with overview everyone, XXXX by during update. before I'll for and you thank financial the conclude recent we review thanks introduction. thoughts to turning solid for begin an operational we will the momentum an generated Q&A.
Total of This Our million, to dividends. over utilization and adoption the are systems. demand performance we efforts an therapy, of efficacy NeuroStar steady broader our the increased was generating $X.X continued revenue reflecting for demand revenue outstanding the solid are of by $XX.X XXXX. of drive million, quarter NeuroStar increase XX% and commercial new the NeuroStar was reflects ongoing paying first team. execution system
our result change systems slightly having well credit challenges late plan XX as as healthcare customers experienced below quarter, quarter, a the some number due in February. negative During a to systems per securing XX as incident for impact purchases by shipped XX of to the partially we of cybersecurity of the customers capital
providers well have down. shut portal on on submissions both of claim patient incident, as seen this of an investigation being as due result eligibility a As benefits the patient impact to determination collections
and is this significantly ability as cash provider's been negatively During collect time, has impacted today. to impaired being of still
of restored article service, providers the Association care the are practices in the our Healthcare's which providers order to that payment. collections on at of the XX% providers. Despite rent Change had they XX% in NeuroStar face patient cash treatment. challenges impacted and American to purchase planned announcement survey claims result of discussing claim were of barriers impact of and Healthcare They with cash. use to to further cover with conducted facing health reduced essential still to due an eligibility results psychiatry submissions of published from a As customers. still To XX% end ability Change collect payroll, in of reallocate verifying costs emphasize disruption forced situation, to April, found Medical experience many providers providers, survey to like for the the continue a
systems Change As systems still to target Ultimately, we the roughly XXX shipping to Healthcare return headwinds of due we in expect to that XX expect we'll subside, to ship our quarter. XX XXXX. per
systems other growth XX and NeuroStar Our mental of summits educating the key a against professionals depression we been States. capital have we the Since disorders. in sales over NeuroStar began hosting our increasing steadily conducted have we and health quarter. events, by numbers the care health adoption United summits, of a have generating of power total XXX million in with $XX driver sold for about each battle summits across these Through these systems,
million of relationships result summit to leading $XX.X a customer New have as we in treat revenue. session these patients, treatment the formed to have over X,XXX enabled practices
Phoenix, mid-May scheduled fully with XX Our next in is for Arizona, Summit attendees. already booked
XX% currently the treat Importantly, adolescents. of attendees
have of those as very for to to pleased NeuroStar are only positively depression. potential adolescent the from interest initial We educate treatment with technology our and its their Overall, continued patients. them for by begun we are just on impact the encouraged demand we battling the psychiatrists the the benefits
nation's currently XX for TMS all and converted be provider agreement, their They In Transformations update of of to a Network, March, in X-year Transformations partnership the a exclusive primarily NeuroStar we fixed price Neuronetics the soon Northeast to the health XX mental has as network. Also, consumable Care model Northwest agreement, Turning XX operate across with partnerships. across systems. on of announced care Transformation's part new from new U.S., exclusive to locations, systems and our an now largest Pacific systems. have the one commercial a In their this of is providers.
as care the their best plans with mental seek a long-standing and the provide of with forward they access an had deliver are part we health excited to moving that exceptional become possible NeuroStar have Transformations, bigger patients very We relationship solutions. will to increasingly their and
This treatment session was consumable growth outside a increase revenue year-over-year the $XX XX% a which validating fueled than of revenue, local highest U.S. by of our to of year-over-year commercial initiatives. quarter mainly the represents in was compared XX% COVID, XXXX. the increase increase million, effectiveness more first
growth cash conserve While remained did mentioned strong, anecdotally the treatment we session just have many that from authorizations of been customers, of a demand as some heard result that therapy slow the for into slower as those moving prior but collections. remains we result note patients issue providers of treatment revenue impact discussing from patient to strong, with have a insurers. delayed situation care health sought I changed When as capital
let's TMS Me standards who collaboration for focus Me to or beginning Guarantee Provider it the Now developed Provider with nationwide The to Better to and shift a updates, establish consistent our group Program expert and aims most. accounts Program in at BMGP. Guarantee operational timely of delivering responsiveness with clinicians following an need care Pilot update those aimed patient Better care
standards prior actively participating our cohort who both program. late the As enroll as well the have will we January. to approximately XXXX, This the of January another early XXX call, second earnings of sites of in last XXX sites officially initial BMGP met more made Greenbrook phase the April, that are launched phase up XXX currently launch as we additional from qualification XX. the In accounts than the and in discussed during included pilot in sites sites
follow-up be We the and related continue out potential responsiveness trends coming the in positive to are the with with to particularly thrilled timely more sites significant we seeing the enrolled patients. of pilot,
to able customer from patient days took faster from being of average a being On last versus across BMGP Historically, non-BMGP more completing a sites Because from sites completed improvement days connecting year. sites. know to our base treatment our average seeing hours are can in to are is sites sites, average, move X.Xx XX using interest interested quickly of Provider for process which NeuroStar to patients, we test are rapidly on they This critical with Xx facilitating to treatment to XX patients motor follow-up suffering Me now in these patient begin an a Better we saw Guarantee them more and up treatment. educate within have XX threshold the it in is patients health conditions. BMGP BMGP a mental than move patient NeuroStar.
threshold a motor completed. result, patients' lives number faster As sites access providers treatment. BMGP improving are the tests are seeing of being XX% to life-changing improvement a them providing in with potentially These by
expand of we program to the pilot as While the number customers continued the year, greater impact are of meaningful the working closely the in to program we employed continue being a tactics highlights a of positive that success the way. monitor throughout
the of NeuroStar all to phase key be agreed pilot standards program. X will to the meet forward, Moving customers the who open
program to We effectively approach will of to to measured we broader continue standards. balance while rollout demand upholding a ensure a take the
bringing in will We of launch June, participating sites the sites to over group XXX. total another of XXX number
our tools, and initiatives. Turning marketing benefits our clinical practices This NeuroStar of X-star enhance programs by to to the best program well customers' educational offered attention understanding which as continues solution, as includes University. our
that receiving participated. to utilization have seeing as material in result sites a As NSU, compared who increases customers of the not are education at are we
more customers this, of set benefits for attendees learn in clinical learned utility that NeuroStar course. able In team seen have the we best patients firsthand educate fact, system. NSU sites not a are NSU more a additional using sites from of how the members on are we with they This on Because utilization classes practices educate who derive. with Neuronetics, to having that to average, compared to as and XX% increase prior able and they becoming partnering are of to attended attendees, seeing our latest our the XX% because to benefit have trend techniques of sites about repeat attended underscores the to
and we Moving to to utilization. forward, success NS's increased adoption continue will drive leverage
for our it saw patient a with prospective practices NeuroStar double remains on At critical should which by easier making our ultimately to program. educate quarter, and During our of we X The co-op and the the matching based for help to of XXXX, a our marketing return the patients. marketing beginning feedback getting successful awareness customers, we introduced and from dollars we greater first by having commitment reinforces customer a awareness practice. And streamlined improvements strategy our even significant within NeuroStar. lead participate, developing reasons: approach, second, it turnkey are program marketing program use continued to drive customers' effectively component to commercial First, co-op to of the their spend, a TMS key invested on our program their strength
approximately of quarter, of end XXX sites participating. have first the As we the
XXXX, of saw grows, during quarter. number across participate utilization metrics. participation we marketing, Those threshold co-op during QX year-over-year a are key first of both in a accounts and the of XXXX As the and see who continuing tests uplift increase QX to motor both in
Turning to our regulatory and clinical update.
in of March, XXX(k) years. end X the we of our received FDA the As past clearance eighth
indication new from treatment is a XX first-line adolescent adjunct for major NeuroStar patients for suffering aged depressive disorder. are as XX who Our to
requiring population, a only without For This of in this the combination NeuroStar for patients has this are milestone failed has set used Adolescent since to Currently, the and can for a this health and is clinicians treatment and complex estimated advancement within paradigm age million be therapies and depression that adolescent prior pandemic. and to the with significant as for for courses depression patient the condition patients, new its in patient prevalence population. company address first available extremely an more TMS other growing this treatment a COVID-XX States mental adolescents large limited, how be is United options cleared is NeuroStar group. X.X potential importantly, the treatment accelerating medication. been impacts
the XX% the real-world within patient TrakStar approximately over With our of our full power a total by depression treatment. and used on with the combined within is showed following clinical the highlights published to immense value proprietary first-line patients in using and Leveraging our and the TMS that of particular, a data and This to commitment was effective we data from evaluating testament increasing our that the adolescent addressable of This meaningful highlights therapy. TrakStar of adolescent evidence treated Trakstar. increased course are demonstrate on analysis making literature improvement a the NeuroStar, the we clearance scale years clinical accumulating achieved size X data in patients FDA's X,XXX team XX%. data new was Trakstar were consider utilize clinical MDD to market has in when in in adolescent safe real-world their and population, our strategy. Relying who clearance of ad advancement for platform, of our NeuroStar regulatory indications,
our Trakstar repository the more health customers' and additional to data, treat NeuroStar daily applicable We to therapy conditions. widely of from opportunities will mental administering of to NeuroStar evaluate use leverage to make real-world continue growing
to Moving MDD the that forward, as we sufferers will and their well educate parents benefits adolescent deliver. work as NeuroStar on clinicians can
the exist adolescent may nurse States, and opportunity the clearance, are approximately encouraging. current there have psychiatrists option recent them. physician we To from now have additional had received have patient extremely that customers interest providers X,XXX within received the our from and we customer providers, population United Beyond both practitioners the community available we in to X,XXX The to current date, adolescent an dozens no already TMS interest to of has the prospects. educate. adolescent practices, been Prior who
population, have clarify age group. use providers, supporting seminar week clearance. customers TMS adolescent This adolescent clinicians treatment physician we data for roughly appreciation for To educate current being to allowed attendees being a NeuroStar held adolescent X/X common from indication. strong approved their over while further expressed review new and around this us have specifics options incorporate prospective indication as questions The the others underserved had users, for for to our to highlighting this clinical with sought the in practices webinar XXX patients. Some NeuroStar look last address X/X this for interest expanding to
education expanding launch XX practices and that parents. We to have includes awareness a increasing comprehensive and our and treat up indication strategy adolescents for among
editors feature experience NeuroStar. amplify significant from is from NeuroStar has NeuroStar top a about consumer and about is MDD writers perspectives and and key a which social To hosting in psychiatrist, get need a awareness more higher with XXXX. are indication from and treatment. York in about a transformative outreach of the in their in at leading will parent media to everyone and advocate event initial a and knows a our New will event newsworthy representative most and the on event that benefits XX since the families, increase patient press MDD top accompanied their trade from an media understanding outlets. treatment. City health NeuroStar by new level will This coverage anticipate We help of sufferers media people help reach to suffering on goal clearance we May education, and This our ensure platforms, digital the Our
in indication to see business the in positive contribution some more will be year, half expect this believe the second and of new We from the material we our impact XXXX. on even
predictor treatment using treatment improvement NeuroStar of After the outcome. it the journal quarter, stimulation, if completing brain therapy. The premier the the clinical announced we of confirmed criticality early the MDD their some in neuromodulation, first show full the when analysis in a field publication of patients in symptoms, end was strong course that a of in successful of patients a highlighting findings of significant
that that experienced reinforces a course which levels meaningful number best in BMGP on data educate one the of once full This early shows patients a they which a data benefits course the had their the program, of of of clinicians completing outcomes. XX the required provides are pillars ultimately the improvement of in treatment confirmed also completed treatments, a clinical low of substantial symptoms is to who course, therapy. it full Importantly, reduction of patients
educate and finishing this we course to continue With to the treatment. benefits data, clinicians will full work of a of on patients
about excited were to during quarter. the accomplish are we able first We what
of result performance of financial solid as successful and deliver initiatives. execution our educational to the awareness continue a We
suffering only with better and validates that, also efficacy but to only manufacturer indication approval. NeuroStar TMS growing This safety XX- the the MDD. provide to of adolescent milestones of clinicians and being first XX-year-olds allows population achieved an help significant Beyond we us not by the care from to
progress to made expanding with and access also increasing agreements We partnerships in commercial care NeuroStar.
call like turn to excited We incredibly With over at Neuronetics. that, Steve. about I'd to the are the future
